Myelomeningocele Clinical Trial
— CuReOfficial title:
Phase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal Myelomeningocele
Spina bifida, or myelomeningocele (MMC), is a disorder where the lower part of the spinal cord of the fetus is exposed, meaning there is no bone or skin covering it. This is dangerous because the spinal cord contains cells which control one's ability to move their legs and walk, and also to be able to urinate and have bowel movements normally. One of the current treatments for fetal MMC is to perform a surgery on the fetus before it is born which has many names including in utero surgery, prenatal surgery, or fetal surgery. This is a surgery that occurs inside the uterus (the womb) where the surgeon closes the opening in your fetus' back to cover the exposed spinal cord. Researchers have found that adding stem cells to the repair is effective in improving the ability of animals with MMC to walk, and that the stem cells are safe in animal studies. These stem cells are thought to protect the cells in the spinal cord that control movement and developmental outcomes. This study is being performed to look at the safety and effectiveness of stem cells on the fetus's exposed spinal cord during prenatal surgery.
Status | Recruiting |
Enrollment | 55 |
Est. completion date | March 2024 |
Est. primary completion date | March 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Weeks to 25 Weeks |
Eligibility | Inclusion Criteria: Eligibility for fetal surgery per the MOMS trial, which are: - Myelomeningocele (including myeloschisis) at any level from T1 through S1 with hindbrain herniation. Lesion level will be confirmed by ultrasound and hindbrain herniation will be confirmed by MRI at the UC Davis Fetal Center - Maternal age =18 years - Gestational age at enrollment between 19 weeks 0 days and 25 weeks 6 days gestation as determined by clinical information and evaluation of first ultrasound - Normal karyotype. Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is greater than 24 weeks gestation; Exclusion Criteria: Not being eligible for fetal surgery per the MOMS trial, which includes: - Multifetal pregnancy - Insulin dependent pregestational diabetes - Fetal anomaly not related to myelomeningocele. - Kyphosis in the fetus of 30 degrees or more - Current or planned cerclage or documented history of incompetent cervix, placenta previa or placental abruption - Short cervix < 20 mm measured by cervical ultrasound - Obesity as defined by body mass index of 35 or greater - Previous spontaneous singleton delivery prior to 37 weeks - Maternal-fetal Rh isoimmunization, Kell sensitization or a history of neonatal alloimmune thrombocytopenia - Maternal HIV or Hepatitis-B status positive due to the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis B status is unknown, the patient must be tested and found to have negative results before she can be enrolled - Known Hepatitis-C positivity. If the patient's Hepatitis C status is unknown, she does not need to be screened - Uterine anomaly such as large or multiple fibroids or Müllerian duct abnormality - Other maternal medical condition which is a contraindication to surgery or general anesthesia. This includes any patient with a previous hysterotomy in the active segment of the uterus (whether from a previous classical cesarean, uterine anomaly such as an arcuate or bicornuate uterus, major myomectomy resection, or previous fetal surgery) - Patient does not have a support person (e.g., husband, partner, mother) - Inability to comply with the travel and follow-up requirements of fetal surgery - Patient does not meet other psychosocial criteria (as determined by the psychosocial interviewer) to handle the implications of fetal surgery - Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy; - Maternal hypertension which would increase the risk of preeclampsia or preterm delivery (including, but not limited to: uncontrolled hypertension, chronic hypertension with end organ damage and new onset hypertension in current pregnancy) - Active COVID-19 infection at time of fetal surgery as determined by positive test |
Country | Name | City | State |
---|---|---|---|
United States | UC Davis Health | Sacramento | California |
Lead Sponsor | Collaborator |
---|---|
Diana Lee Farmer | California Institute for Regenerative Medicine (CIRM) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety of the placenta-derived mesenchymal stem cell (PMSC-ECM) Product | Will be assessed by evaluating the presence or absence of cerebrospinal fluid leak, infection at the MMC repair site, failure of the MMC repair site to heal, and any unexpected growths or tumor formation. These will be assessed at birth by physical exam, brain and spinal ultrasound , and brain and spinal MRI. | Assessed at birth | |
Secondary | Efficacy of the PMSC-ECM Product | This is primarily evaluated by improvement in motor function 2 or more levels greater than expected by anatomic level of the defect and by patients' ability to walk independently. Bowel function will be assessed by caregiver questionnaires on bowel habits, and by anorectal manometry. Urologic function will be assessed by caregiver questionnaires regarding urologic function, by renal and bladder ultrasounds to evaluate for hydronephrosis and bladder abnormalities, and by video urodynamics. | 30 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06042140 -
Cryopreserved Human Umbilical Cord as a Meningeal Patch in Fetoscopic Spina Bifida Repair
|
N/A | |
Recruiting |
NCT03562286 -
Open Spina Bifida Fetoscopic Repair Project
|
N/A | |
Completed |
NCT04468568 -
In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline
|
||
Recruiting |
NCT04362592 -
In-Utero Endoscopic Correction of Spina Bifida
|
N/A | |
Recruiting |
NCT03856034 -
Laparotomy Versus Percutaneous Endoscopic Correction of Myelomeningocele
|
N/A | |
Active, not recruiting |
NCT03936322 -
Minimally Invasive Fetoscopic Regenerative Repair of Spina Bifida - A Pilot Study
|
N/A | |
Not yet recruiting |
NCT06405698 -
Role of Perforator Flaps in Back Defects Reconstruction
|
N/A | |
Active, not recruiting |
NCT00175123 -
Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele
|
Phase 4 | |
Completed |
NCT02390895 -
Prenatal Endoscopic Repair of Fetal Spina Bifida
|
N/A | |
Active, not recruiting |
NCT03090633 -
Fetoscopic Repair of Isolated Fetal Spina Bifida
|
N/A | |
Not yet recruiting |
NCT03088761 -
Cuff Pressure in Infants
|
N/A | |
Active, not recruiting |
NCT04484441 -
Maternal-fetal Immune Responses to Fetal Surgery
|
||
Recruiting |
NCT04738539 -
Efficacy of Contrast Enhanced Voiding Urosonography for Urodynamic Studies
|
||
Terminated |
NCT02493062 -
Evaluation of Hysterotomy Site After Open Fetal Surgery
|
N/A | |
Completed |
NCT03550898 -
Can Dynamic Ultrasonography Replace Urodynamics in Follow-up of Patients With Myelomeningocele
|
N/A | |
Active, not recruiting |
NCT04251806 -
Sleep-disordered Breathing in Infants With Myelomeningocele
|
||
Terminated |
NCT02509377 -
Fetal Myelomeningocele Repair With Maternal BMI Between 35.0 and 40.0
|
N/A | |
Recruiting |
NCT03788122 -
Fetal Surgery Interview Study: Parental Perceptions of Fetal Surgery
|
N/A | |
Completed |
NCT02664207 -
Extended Criteria For Fetal Myelomeningocele Repair
|
N/A | |
Recruiting |
NCT03315637 -
Fetal Endoscopic Surgery for Spina Bifida
|
N/A |